Assessment of hemostatic risk factors in predicting arterial thrombotic events

被引:96
作者
Feinbloom, D
Bauer, KA
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA
关键词
arterial; thrombosis; atherosclerosis; hemostasis; risk factors;
D O I
10.1161/01.ATV.0000181762.31694.da
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Arterial thrombosis results from endovascular injury and, to a lesser extent, alterations in hemostatic equilibrium. Although multiple hereditary and acquired hemostatic risk factors have been described in the pathophysiology of venous thrombosis, the degree and type of abnormalities that contribute to arterial thrombosis are less well understood. Endothelial cell injury with the elaboration of proinflammatory mediators stimulates the process of arterial thrombosis. Although this is most often the result of endovascular injury attributable to atherosclerotic disease, other disease states can elicit a similar response as well. Similarly, once thrombosis has been initiated, variations in the activity of coagulation proteins and endogenous anticoagulants, as well as the kinetics of platelet aggregation, may alter the effectiveness of thrombus formation. Epidemiological studies have identified several acquired or inherited states that may result in endothelial damage or altered hemostatic equilibrium, thereby predisposing patients to arterial thrombosis. These include hyperhomocysteinemia, elevated C-reactive protein, antiphospholipid antibodies, elevated fibrinogen, Factor VII, plasminogen activator inhibitor-1 (PAI-1), hereditary thrombophilias, and platelet hyper-reactivity. This review explores our present understanding of these risk factors in the development of arterial thrombotic events. At present, the literature supports a role for hyperhomocysteinemia, elevated C-reactive protein, and elevated fibrinogen as risk factors for arterial thrombosis. Similarly, the literature suggests that lupus anticoagulants and, to a lesser extent, elevated titers of cardiolipin IgG antibodies predispose to arterial vascular events. In certain subsets of patients, including those with concomitant cardiac risk factors, < 55 years of age, and women, hereditary thrombophilias such as carriership of the factor V Leiden and the prothrombin G20210A mutations may confer a higher risk of arterial thrombosis. However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking.
引用
收藏
页码:2043 / 2053
页数:11
相关论文
共 128 条
  • [111] Homocysteine and atherothrombosis - mechanisms for injury
    Thambyrajah, J
    Townend, JN
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (12) : 967 - 974
  • [112] High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women -: Evidence for the fibrinolytic system as an independent primary risk factor
    Thögersen, AM
    Jansson, JH
    Boman, K
    Nilsson, TK
    Weinehall, L
    Huhtasaari, F
    Hallmans, G
    [J]. CIRCULATION, 1998, 98 (21) : 2241 - 2247
  • [113] C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction
    Tommasi, S
    Carluccio, E
    Bentivoglio, M
    Buccolieri, M
    Mariotti, M
    Politano, M
    Corea, L
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (12) : 1595 - 1599
  • [114] Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death - The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial
    Toole, JF
    Malinow, MR
    Chambless, LE
    Spence, JD
    Pettigrew, LC
    Howard, VJ
    Sides, EG
    Wang, CH
    Stampfer, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (05): : 565 - 575
  • [115] Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events
    Torres, JL
    Ridker, PM
    [J]. CURRENT OPINION IN CARDIOLOGY, 2003, 18 (06) : 471 - 478
  • [116] CROSS-REACTION BETWEEN ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN AND TO CARDIOLIPIN IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    VAARALA, O
    ALFTHAN, G
    JAUHIAINEN, M
    LEIRISALOREPO, M
    AHO, K
    PALOSUO, T
    [J]. LANCET, 1993, 341 (8850) : 923 - 925
  • [117] ANTICARDIOLIPIN ANTIBODIES AND RISK OF MYOCARDIAL-INFARCTION IN A PROSPECTIVE COHORT OF MIDDLE-AGED MEN
    VAARALA, O
    MANTTARI, M
    MANNINEN, V
    TENKANEN, L
    PUURUNEN, M
    AHO, K
    PALOSUO, T
    [J]. CIRCULATION, 1995, 91 (01) : 23 - 27
  • [118] ANGIOTENSIN-II REGULATES THE EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN CULTURED ENDOTHELIAL-CELLS - A POTENTIAL LINK BETWEEN THE RENIN-ANGIOTENSIN SYSTEM AND THROMBOSIS
    VAUGHAN, DE
    LAZOS, SA
    TONG, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) : 995 - 1001
  • [119] Antiphospholipid antibodies in acute coronary syndrome
    Veres, K
    Lakos, G
    Kerényi, A
    Szekanecz, Z
    Szegedi, G
    Shoenfeld, Y
    Soltész, P
    [J]. LUPUS, 2004, 13 (06) : 423 - 427
  • [120] Elevated C-reactive protein levels in overweight and obese adults
    Visser, M
    Bouter, LM
    McQuillan, GM
    Wener, MH
    Harris, TB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (22): : 2131 - 2135